First Patient Dosed with VS-7375 in Ph 1/2a Trial in KRAS G12D Advanced Solid Tumors
“We continue to make strong progress against our strategic priorities and key milestones that we set at the beginning of the year, including our recent FDA approval and commercial launch and our positive updated results and trial expansion in first-line metastatic pancreatic cancer. We are now excited to have achieved another milestone with the initiation of our first clinical trial and first patient dosed with VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, in the U.S.,” said Dan Paterson, president and chief executive officer of Verastem Oncology.
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines